One-Stop shot: trial tests giving COVID and flu vaccines together
NCT ID NCT06279871
Summary
This large Phase 3 study tested a new type of COVID-19 booster vaccine (ARCT-2303) that uses self-amplifying RNA technology. Researchers wanted to see if it was safe and effective when given at the same time as a seasonal flu shot. The study involved over 1,500 adults who had already been vaccinated against COVID-19, comparing immune responses and side effects across different groups.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Australian Clinical Research Network (ACRN)
Sydney, New South Wales, Australia
-
Austrials - St. Leonards
Sydney, New South Wales, Australia
-
Austrials -Sunshine
Melbourne, Victoria, Australia
-
CMAX
Adelaide, South Australia, Australia
-
Clinitrials - Mount Site
Perth, Western Australia, Australia
-
Clínica San Agustín
San José, Costa Rica
-
Deposito de Medicamentos de Investigación Cousin Agustín (DEMEDICA)
San Pedro Sula, Honduras
-
Emeritus Research Melbourne
Melbourne, Victoria, Australia
-
Emeritus Research Sydney
Sydney, New South Wales, Australia
-
Far Eastern University - Nicanor R. M Foundation
Quezon City, Philippines
-
Griffith University Clinical Trials Unit
Sydney, New South Wales, Australia
-
IICIMED
San José, Costa Rica
-
Inversiones en Investigación Médica S.A (INVERIME)
Tegucigalpa, Honduras
-
Northern Beaches Clinical Research - Walski
Sydney, New South Wales, Australia
-
Nucleus Network
Melbourne, Victoria, Australia
-
Nucleus Network Brisbane (Q-Pharm)
Brisbane, Queensland, Australia
-
Organización y centro de investigación clínica Ochoa (OCINCO)
Comayagua, Honduras
-
Paratus Clinical Blacktown
Sydney, New South Wales, Australia
-
Paratus Clinical Brisbane
Brisbane, Queensland, Australia
-
Paratus Clinical Canberra
Canberra, Australian Capital Territory, Australia
-
Paratus Clinical Central Coast
Central Coast, New South Wales, Australia
-
Sutherland Shire Clinical Research - Walski
Miranda, New South Wales, Australia
-
The Peter Doherty Institute for Infection and Immunity
Melbourne, Victoria, Australia
-
Tropical Disease Foundation - Putatan Health Center
City of Muntinlupa, Philippines
-
USC Morayfield
Morayfield, Queensland, Australia
-
USC Sippy Down
Sunshine Coast, Queensland, Australia
-
USC Southbank
Brisbane, Queensland, Australia
-
Veritus Research
Melbourne, Victoria, Australia
-
Wollongong Clinical Research
Wollongong, New South Wales, Australia
Conditions
Explore the condition pages connected to this study.